The Lynx Group
Cholangiocarcinoma News

Web Exclusives

Web Exclusives — November 9, 2021
On November 3, 2021, TransThera Sciences announced that the FDA granted its investigational drug, TT-00420, a spectrum-selective multi-kinase inhibitor, a fast-track designation for the treatment of patients with cholangiocarcinoma (CCA) who have no available standard treatment options. In preclinical studies, TT-00420 has shown high activity in a variety of FGFR mutations.
Read More

Web Exclusives — October 28, 2021
On October 25, 2021, AstraZeneca announced high-level positive results from the phase 3 clinical trial TOPAZ-1, demonstrating that adding the immunotherapy durvalumab (Imfinzi) to first-line standard-of-care chemotherapy leads to a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone in patients with advanced biliary tract cancer.
Read More

Web Exclusives — August 30, 2021
Ivosidenib has been approved by the FDA for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
Read More

Web Exclusives — February 3, 2021
February 1, 2021 (Cranbury, NJ): The Cholangiocarcinoma Foundation (CCF) designated The Lynx Group (TLG) as a “Trusted Partner,” 1 of only 4 organizations globally. A CCF “Trusted Partner” shares the CCF mission: to find a cure and improve the quality of life for those affected by cholangiocarcinoma (CCA). These 4 esteemed partners are fundamental to the Foundation’s growth and ability to provide high-quality programs and services to the CCA community.
Read More

Web Exclusives — December 23, 2020
As the end of this year draws near, we at The Lynx Group would like to take this opportunity to thank all of you for an amazing 2020. We also share a celebration of our victories and accomplishments with everyone, while reflecting on ways to improve as we progress into the new year! The success of The Lynx Group is based on the effective and vibrant relationships we have forged over the years; we simply wouldn’t be where we are without you. We are extremely grateful for the opportunity to work with, and for you!
Read More

Web Exclusives — May 30, 2020
The combinations of nivolumab with gemcitabine/cisplatin or nivolumab with ipilimumab were tested in patients with untreated advanced biliary tract cancer.
Read More

Web Exclusives — May 30, 2020
The response rate to the combination of ipilimumab and nivolumab in patients with advanced biliary tract cancer compared favorably to clinical trials investigating single-agent anti–PD-1 therapy.
Read More

Web Exclusives — May 30, 2020
Durvalumab ± tremelimumab plus chemotherapy was well-tolerated and showed promising efficacy in chemotherapy-naïve patients with advanced biliary tract cancer.
Read More

Web Exclusives — May 30, 2020
Detection of IDH1 mutations in plasma from patients with intrahepatic cholangiocarcinoma is highly concordant with detection in tumor tissue.
Read More

Web Exclusives — May 28, 2020
In a phase 2 trial of patients with cholangiocarcinoma and FGFR2 fusions, infigratinib administered as third- and later-line chemotherapy treatment resulted in a meaningful progression-free survival and objective response rate benefit.
Read More

Page 1 of 3

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: